Unlocking the Future of the Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market: Growth Rate, Key Trends, and Opportunities for 2025-2034
Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!
How has the cell and gene therapy contract development and manufacturing organization (cdmo) market grown over the years?
The cell and gene therapy contract development and manufacturing organization (CDMO) market has seen exponential growth in recent years. It will increase from $5.41 billion in 2024 to $6.94 billion in 2025, reflecting a compound annual growth rate (CAGR) of 28.2%. The historical growth is attributed to technological advancements, favorable regulatory frameworks, greater investment in the sector, the high prevalence of genetic disorders, and a rising number of strategic partnerships.
What Is the forecasted market size and growth rate for the cell and gene therapy contract development and manufacturing organization (cdmo) market?
The cell and gene therapy contract development and manufacturing organization (CDMO) market is forecast to grow to $18.54 billion by 2029 at a CAGR of 27.8%. This growth is driven by expanded therapeutic applications, regulatory evolution, technological innovations, and global collaboration. Trends include increased demand for personalized therapies, automation and digitalization, manufacturing capacity expansion, novel delivery systems, and sustainability.
Get your cell and gene therapy contract development and manufacturing organization (cdmo) market report here!
What are the major factors driving growth in the cell and gene therapy contract development and manufacturing organization (cdmo) market?
The increasing prevalence of cancer is set to drive the growth of the cell and gene therapy contract development and manufacturing organization (CDMO) market. The rise in cancer cases is linked to aging populations, lifestyle changes, and better detection methods. CDMOs play a role in developing targeted therapies for cancer that improve treatment efficacy. For instance, in October 2022, Macmillan Cancer Support projected that the number of people living with cancer in the UK would rise from 3 million in 2022 to 5.3 million by 2040. The increasing cancer burden is driving the CDMO market.
What key areas define the segmentation of the global cell and gene therapy contract development and manufacturing organization (cdmo) Market?
The cell and gene therapy contract development and manufacturing organization (CDMO) market covered in this report is segmented –
1) By Product Type: Gene Therapy, Gene-Modified Cell Therapy, Cell Therapy
2) By Phase: Phase 1, Phase 2, Phase 3, Phase 4
3) By Indication: Oncology, Infectious Diseases, Neurological Disorders, Rare Diseases, Other Indications
Subsegments:
1) By Gene Therapy: Viral Vector-Based Gene Therapy, Non-Viral Gene Therapy, Plasmid DNA-Based Gene Therapy
2) By Gene-Modified Cell Therapy: CAR-T Cell Therapy, TCR-T Cell Therapy, NK Cell Therapy
3) By Cell Therapy: Stem Cell Therapy, Progenitor Cell Therapy, Immune Cell Therapy
Get your free sample now – explore exclusive market insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15753&type=smp
What are the top market players propelling the growth of the cell and gene therapy contract development and manufacturing organization (cdmo) industry?
Major companies operating in the cell and gene therapy contract development and manufacturing organization (CDMO) market are Pfizer Inc., Merck & Co. Inc., Thermo Fisher Scientific Inc., Novartis AG, FUJIFILM Diosynth Biotechnologies, AGC Biologics, Ajinomoto Co Inc., Lonza Group, Catalent Inc., Charles River Laboratories International Inc., Sartorius Stedim Biotech, Samsung Biologics Co Ltd., WuXi Biologics, Recipharm AB, Almac Group Ltd., KBI Biopharma, Rentschler Biopharma, Bio Elpida, Oxford BioMedica Plc, Avid Bioservices Inc., Cell and Gene Therapy Catapult, VGXI Inc., Genezen Laboratories Inc., Pluri Inc., OmniaBio Inc.
What are the key trends shaping the future of the cell and gene therapy contract development and manufacturing organization (cdmo) market?
Companies in the cell and gene therapy contract development and manufacturing organization (CDMO) market are expanding their portfolios with technologies like PluriMatrix to boost scalability and manufacturing efficiency. PluriMatrix is a proprietary technology for large-scale cell-based product production. For instance, in January 2024, Israel-based Pluri introduced PluriCDMO, a new division offering cell therapy manufacturing services. The division includes a GMP-certified facility and provides end-to-end services, including preclinical to commercial-scale production, process validation, and regulatory support.
Unlock exclusive market insights – purchase your research report now for a swift delivery!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=15753
What regions are dominating the cell and gene therapy contract development and manufacturing organization (cdmo) market growth?
North America was the largest region in the cell and gene therapy contract development and manufacturing organization (CDMO) market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cell and gene therapy contract development and manufacturing organization (CDMO) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Browse Through More Similar Reports By The Business Research Company:
Cellular or Mobile Telephone Services Global Market Report 2024
Cell And Gene Therapy Supply Chain/Logistics Global Market Report 2024
Cell and Gene Therapy Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/cell-and-genes-therapy-global-market-report
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
